{
    "nctId": "NCT00994968",
    "briefTitle": "Doxorubicin Hydrochloride, Cyclophosphamide, Docetaxel, and S-1 Before Surgery in Treating Women With Stage II or Stage III Breast Cancer",
    "officialTitle": "Neoadjuvant Doxorubicin and Cyclophosphamide Followed by Docetaxel and S-1 in Breast Cancer",
    "overallStatus": "UNKNOWN",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "N/A",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 49,
    "primaryOutcomeMeasure": "Rate of pathologic complete response",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Histologically or cytologically confirmed invasive primary breast cancer\n\n  * Clinical (radiologic) stage II or III disease\n  * No T4d disease\n  * No inflammatory breast cancer\n* ErbB2-negative disease OR patient cannot receive trastuzumab treatment\n\n  * ErbB2-positive disease defined as either immunohistochemistry 3+, or FISH- or CISH-positive; immunohistochemistry 2+ is to be determined according to FISH or CISH results\n\nPATIENT CHARACTERISTICS:\n\n* Mobile\n* ECOG performance status 0-1\n* Normal cardiac function (LVEF \\> 50%)\n* Hemoglobin \u2265 10.0 g/dL\n* Absolute neutrophil count \u2265 1,500/\u03bcL\n* Platelet count \u2265 10 x 10\\^4/\u03bcL\n* Creatinine \u2264 1.5 times upper limit of normal (ULN) OR creatinine clearance \u2265 50 mL/min\n* Total bilirubin \u2264 1.5 times ULN\n* AST/ALT \u2264 2.5 times ULN\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective contraception\n* Able to swallow tablet whole with water\n* No prior motor or sensory neurotoxicity CTCAE \u2265 grade 2\n* No other serious disease or medical condition\n* No uncontrolled or serious cardiovascular disease, including any of the following:\n\n  * Myocardial infarction within the past 6 months\n  * New York Heart Association class III or IV heart failure\n  * Uncontrolled angina pectoris\n  * Clinically significant pericardial disease\n  * Cardiac amyloidosis\n* No history of symptomatic or therapy-requiring cardiac arrhythmia CTCAE grade 3 (e.g., multifocal premature ventricular contractions, bigeminy, trigeminy, ventricular tachycardia, uncontrolled atrial fibrillation)\n* No asymptomatic sustained ventricular tachycardia\n* History of atrial fibrillation or cardiac arrhythmia controlled by medication allowed\n* No uncontrolled infection, unstable peptic ulcer, uncontrolled diabetes, or any other contraindication to corticosteroid administration\n* No history of infection or any other serious medical event which may cause any functional injury in the affected patient and consequently, interfere with continuing the study treatment\n* No history of hypersensitivity to taxanes, fluorouracil, or S-1\n* No significant gastrointestinal malfunction that will affect S-1 absorption\n* No history of other cancer within the past 5 years except properly treated carcinoma in situ of the uterine cervix or basal cell or squamous cell carcinoma of the skin\n* No severe psychological or neurological disorder or dementia that would preclude understanding of the informed consent\n* No psychological, social, family, or geographical condition, or difficult circumstance that would preclude follow-up or compliance with the protocol\n\nPRIOR CONCURRENT THERAPY:\n\n* No prior systemic treatment for this cancer (e.g., radiotherapy, chemotherapy, hormone therapy, or biological therapy)\n* No prior preoperative topical treatments (e.g., incomplete surgery or radiotherapy) for this cancer\n* No concurrent drug(s) that may potentially cause changes in the pharmacological activity of S-1 formulation, including any of the following:\n\n  * Allopurinol\n  * Phenytoin",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}